The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups.
Gat I, Shlush E, Quach K, Librach CL.
Syst Biol Reprod Med. 2015;61(6):336-44. doi: 10.3109/19396368.2015.1089607. Epub 2015 Oct 30.
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ, Espejo Valle-Inclan J, Hami N, Lõhmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H, Kloosterman WP, Cuppen E, Snippert HJG, Zweemer RP, Witteveen PO, Stelloo E.
Cell Rep. 2020 Jun 16;31(11):107762. doi: 10.1016/j.celrep.2020.107762.
The normal menstrual cycle in women.
Mihm M, Gangooly S, Muttukrishna S.
Anim Reprod Sci. 2011 Apr;124(3-4):229-36. doi: 10.1016/j.anireprosci.2010.08.030. Epub 2010 Sep 3.
New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
Torkildsen CF, Austdal M, Jarmund AH, Kleinmanns K, Lamark EK, Nilsen EB, Stefansson I, Sande RK, Iversen AC, Thomsen LCV, Bjørge L.
Front Immunol. 2024 Jun 14;15:1394497. doi: 10.3389/fimmu.2024.1394497. eCollection 2024.
Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E.
Nat Commun. 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6.
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine.
Cappuccio S, Distefano MG, Ghizzoni V, Fagotti A, Scambia G.
Gynecol Oncol Rep. 2020 Feb 13;32:100547. doi: 10.1016/j.gore.2020.100547. eCollection 2020 May.
Pathological response of ovarian cancer to neoadjuvant chemotherapy.
Ivantsov AO.
Chin Clin Oncol. 2018 Dec;7(6):59. doi: 10.21037/cco.2018.09.07.
Tumor-intrinsic and -extrinsic (immune) gene signatures robustly predict overall survival and treatment response in high grade serous ovarian cancer patients.
Mysona DP, Tran L, Bai S, Dos Santos B, Ghamande S, Chan J, She JX.
Am J Cancer Res. 2021 Jan 1;11(1):181-199. eCollection 2021.
The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer.
Launonen IM, Vähärautio A, Färkkilä A.
Cold Spring Harb Perspect Med. 2023 Oct 3;13(10):a041314. doi: 10.1101/cshperspect.a041314.
BRCA1 expression, its correlation with clinicopathological features, and response to neoadjuvant chemotherapy in high-grade serous ovarian cancer.
Patil A, Patil S, Anupama CE, Rajarajan S, Nimbalkar VP, Amirtham U, Champaka G, Suma MN, Patil GV, Nargund A, Pallavi VR, Jacob L, Premalatha CS, Prabhu JS.
J Obstet Gynaecol Res. 2023 Dec;49(12):2875-2882. doi: 10.1111/jog.15796. Epub 2023 Sep 22.
